Beam Therapeutics Inc.
BEAM
$31.58
-$0.17-0.54%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 164.01M | 139.74M | 55.70M | 60.27M | 63.58M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 164.01M | 139.74M | 55.70M | 60.27M | 63.58M |
| Cost of Revenue | 321.86M | 326.54M | 328.70M | 313.19M | 298.48M |
| Gross Profit | -157.85M | -186.79M | -273.00M | -252.92M | -234.90M |
| SG&A Expenses | 120.31M | 113.82M | 110.20M | 109.97M | 112.74M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 535.63M | 523.44M | 521.99M | 506.25M | 494.30M |
| Operating Income | -371.62M | -383.69M | -466.29M | -445.98M | -430.72M |
| Income Before Tax | -65.04M | -79.05M | -413.70M | -397.64M | -386.36M |
| Income Tax Expenses | -- | -- | 0.00 | 0.00 | 39.00K |
| Earnings from Continuing Operations | -65.04 | -79.05 | -413.70 | -397.64 | -386.40 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -65.04M | -79.05M | -413.70M | -397.64M | -386.40M |
| EBIT | -371.62M | -383.69M | -466.29M | -445.98M | -430.72M |
| EBITDA | -349.25M | -361.40M | -444.22M | -423.99M | -408.70M |
| EPS Basic | -0.64 | -0.96 | -4.42 | -4.50 | -4.60 |
| Normalized Basic EPS | -0.44 | -0.62 | -2.80 | -2.80 | -2.79 |
| EPS Diluted | -0.69 | -1.01 | -4.42 | -4.50 | -4.60 |
| Normalized Diluted EPS | -0.47 | -0.65 | -2.80 | -2.80 | -2.79 |
| Average Basic Shares Outstanding | 410.71M | 395.42M | 375.37M | 355.20M | 335.52M |
| Average Diluted Shares Outstanding | 412.76M | 397.47M | 375.37M | 355.20M | 335.52M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |